Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
DYAX's Cash to Debt is ranked higher than
96% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. DYAX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
DYAX' s Cash to Debt Range Over the Past 10 Years
Min: 0.27  Med: 2.00 Max: No Debt
Current: No Debt
Equity to Asset 0.90
DYAX's Equity to Asset is ranked higher than
83% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. DYAX: 0.90 )
Ranked among companies with meaningful Equity to Asset only.
DYAX' s Equity to Asset Range Over the Past 10 Years
Min: -1.26  Med: 0.38 Max: 0.9
Current: 0.9
-1.26
0.9
F-Score: 4
Z-Score: 97.32
M-Score: -1.18
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -19.17
DYAX's Operating margin (%) is ranked higher than
61% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. DYAX: -19.17 )
Ranked among companies with meaningful Operating margin (%) only.
DYAX' s Operating margin (%) Range Over the Past 10 Years
Min: -389.57  Med: -85.75 Max: -1.51
Current: -19.17
-389.57
-1.51
Net-margin (%) -30.42
DYAX's Net-margin (%) is ranked higher than
58% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. DYAX: -30.42 )
Ranked among companies with meaningful Net-margin (%) only.
DYAX' s Net-margin (%) Range Over the Past 10 Years
Min: -393.89  Med: -112.02 Max: -14.53
Current: -30.42
-393.89
-14.53
ROE (%) -15.71
DYAX's ROE (%) is ranked higher than
62% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. DYAX: -15.71 )
Ranked among companies with meaningful ROE (%) only.
DYAX' s ROE (%) Range Over the Past 10 Years
Min: -1406.43  Med: -156.29 Max: -17.98
Current: -15.71
-1406.43
-17.98
ROA (%) -10.47
DYAX's ROA (%) is ranked higher than
65% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. DYAX: -10.47 )
Ranked among companies with meaningful ROA (%) only.
DYAX' s ROA (%) Range Over the Past 10 Years
Min: -89.25  Med: -40.76 Max: -6.76
Current: -10.47
-89.25
-6.76
ROC (Joel Greenblatt) (%) -348.05
DYAX's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. DYAX: -348.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DYAX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1121.26  Med: -510.24 Max: -16.77
Current: -348.05
-1121.26
-16.77
Revenue Growth (3Y)(%) 7.60
DYAX's Revenue Growth (3Y)(%) is ranked higher than
60% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. DYAX: 7.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DYAX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -37.4  Med: -3.10 Max: 21.1
Current: 7.6
-37.4
21.1
EBITDA Growth (3Y)(%) -100.00
DYAX's EBITDA Growth (3Y)(%) is ranked lower than
99% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. DYAX: -100.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DYAX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -100  Med: -11.20 Max: 10.4
Current: -100
-100
10.4
EPS Growth (3Y)(%) -36.60
DYAX's EPS Growth (3Y)(%) is ranked lower than
85% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. DYAX: -36.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DYAX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -37.2  Med: -8.60 Max: 11.8
Current: -36.6
-37.2
11.8
» DYAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

DYAX Guru Trades in Q1 2015

Ken Fisher 182,450 sh (New)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 10,632,860 sh (-2.18%)
Chuck Royce 162,200 sh (-9.69%)
» More
Q2 2015

DYAX Guru Trades in Q2 2015

Jim Simons 168,500 sh (New)
Ken Fisher 182,450 sh (unchged)
PRIMECAP Management 10,617,860 sh (-0.14%)
Chuck Royce 68,100 sh (-58.01%)
» More
Q3 2015

DYAX Guru Trades in Q3 2015

Steven Cohen 10,600 sh (New)
Jim Simons 343,308 sh (+103.74%)
Ken Fisher 185,375 sh (+1.60%)
PRIMECAP Management 10,617,860 sh (unchged)
Chuck Royce Sold Out
» More
Q4 2015

DYAX Guru Trades in Q4 2015

Jeremy Grantham 546,377 sh (New)
Mario Gabelli 187,150 sh (New)
Ken Fisher 185,375 sh (unchged)
Jim Simons Sold Out
PRIMECAP Management 10,482,860 sh (-1.27%)
» More
» Details

Insider Trades

Latest Guru Trades with DYAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Dyax Corp

Mario Gabelli Comments on Dyax Corp - Jan 29, 2016

Dyax Corp. (2.2%) (DYAX – $37.62 – NASDAQ) (NASDAQ:DYAX) is a Burlington, Massachusetts based biopharmaceutical company. The company is targeting hereditary angioedema (HAE), a rare, genetic inflammatory condition, via their pipeline drug DX-2930, an injectable treatment for acute HAE. On November 2, 2015, the company received a $5.9 billion cash merger offer by Shire plc, a leading specialty pharmaceutical company with an interest in the HAE space. The offer is structured to include $37.30 cash per share at closing, along with a contingent value right (CVR) potentially worth $4.00. The CVR is tied to the FDA approving DX-2930 by 2019. The deal closed on January 22, 2016.


From Mario Gabelli (Trades, Portfolio)'s ABC Fund Merger and Arbitrage shareholder letter for the fourth quarter 2015.

Check out Mario Gabelli latest stock trades

Top Ranked Articles about Dyax Corp

Mario Gabelli Comments on Dyax Corp Guru stock highlight
Dyax Corp. (2.2%) (DYAX – $37.62 – NASDAQ) (NASDAQ:DYAX) is a Burlington, Massachusetts based biopharmaceutical company. The company is targeting hereditary angioedema (HAE), a rare, genetic inflammatory condition, via their pipeline drug DX-2930, an injectable treatment for acute HAE. On November 2, 2015, the company received a $5.9 billion cash merger offer by Shire plc, a leading specialty pharmaceutical company with an interest in the HAE space. The offer is structured to include $37.30 cash per share at closing, along with a contingent value right (CVR) potentially worth $4.00. The CVR is tied to the FDA approving DX-2930 by 2019. The deal closed on January 22, 2016.
Read more...

Ratios

vs
industry
vs
history
Forward P/E 1666.67
DYAX's Forward P/E is ranked lower than
100% of the 341 Companies
in the Global Biotechnology industry.

( Industry Median: 16.50 vs. DYAX: 1666.67 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 17.95
DYAX's P/B is ranked lower than
99.99% of the 1128 Companies
in the Global Biotechnology industry.

( Industry Median: 2.89 vs. DYAX: 17.95 )
Ranked among companies with meaningful P/B only.
DYAX' s P/B Range Over the Past 10 Years
Min: 2.22  Med: 11.22 Max: 74.67
Current: 17.95
2.22
74.67
P/S 55.67
DYAX's P/S is ranked lower than
88% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 8.77 vs. DYAX: 55.67 )
Ranked among companies with meaningful P/S only.
DYAX' s P/S Range Over the Past 10 Years
Min: 2.46  Med: 8.19 Max: 55.67
Current: 55.67
2.46
55.67
EV-to-EBIT -295.12
DYAX's EV-to-EBIT is ranked lower than
99.99% of the 452 Companies
in the Global Biotechnology industry.

( Industry Median: 18.07 vs. DYAX: -295.12 )
Ranked among companies with meaningful EV-to-EBIT only.
DYAX' s EV-to-EBIT Range Over the Past 10 Years
Min: -2896.7  Med: -6.80 Max: -2
Current: -295.12
-2896.7
-2
EV-to-EBITDA -311.84
DYAX's EV-to-EBITDA is ranked lower than
99.99% of the 479 Companies
in the Global Biotechnology industry.

( Industry Median: 15.17 vs. DYAX: -311.84 )
Ranked among companies with meaningful EV-to-EBITDA only.
DYAX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -22320.3  Med: -6.80 Max: 7594.7
Current: -311.84
-22320.3
7594.7
Current Ratio 11.66
DYAX's Current Ratio is ranked higher than
79% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. DYAX: 11.66 )
Ranked among companies with meaningful Current Ratio only.
DYAX' s Current Ratio Range Over the Past 10 Years
Min: 1.34  Med: 3.69 Max: 18.73
Current: 11.66
1.34
18.73
Quick Ratio 11.15
DYAX's Quick Ratio is ranked higher than
78% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. DYAX: 11.15 )
Ranked among companies with meaningful Quick Ratio only.
DYAX' s Quick Ratio Range Over the Past 10 Years
Min: 1.34  Med: 3.64 Max: 18.58
Current: 11.15
1.34
18.58
Days Inventory 160.39
DYAX's Days Inventory is ranked lower than
61% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. DYAX: 160.39 )
Ranked among companies with meaningful Days Inventory only.
DYAX' s Days Inventory Range Over the Past 10 Years
Min: 202.81  Med: 821.79 Max: 1300.93
Current: 160.39
202.81
1300.93
Days Sales Outstanding 49.31
DYAX's Days Sales Outstanding is ranked higher than
65% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. DYAX: 49.31 )
Ranked among companies with meaningful Days Sales Outstanding only.
DYAX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 37.74  Med: 48.03 Max: 75.98
Current: 49.31
37.74
75.98
Days Payable 36.57
DYAX's Days Payable is ranked lower than
65% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. DYAX: 36.57 )
Ranked among companies with meaningful Days Payable only.
DYAX' s Days Payable Range Over the Past 10 Years
Min: 191.05  Med: 603.30 Max: 1010.44
Current: 36.57
191.05
1010.44

Valuation & Return

vs
industry
vs
history
Price/Net Cash 20.64
DYAX's Price/Net Cash is ranked lower than
80% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: 5.54 vs. DYAX: 20.64 )
Ranked among companies with meaningful Price/Net Cash only.
DYAX' s Price/Net Cash Range Over the Past 10 Years
Min: 3.14  Med: 10.31 Max: 251.33
Current: 20.64
3.14
251.33
Price/Net Current Asset Value 18.91
DYAX's Price/Net Current Asset Value is ranked lower than
83% of the 893 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. DYAX: 18.91 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
DYAX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.56  Med: 8.12 Max: 62.83
Current: 18.91
2.56
62.83
Price/Tangible Book 17.95
DYAX's Price/Tangible Book is ranked lower than
88% of the 1047 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. DYAX: 17.95 )
Ranked among companies with meaningful Price/Tangible Book only.
DYAX' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.05  Med: 5.93 Max: 72
Current: 17.95
1.05
72
Price/Median PS Value 6.80
DYAX's Price/Median PS Value is ranked lower than
97% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 1.24 vs. DYAX: 6.80 )
Ranked among companies with meaningful Price/Median PS Value only.
DYAX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.14  Med: 0.90 Max: 4.76
Current: 6.8
0.14
4.76
Earnings Yield (Greenblatt) (%) -0.30
DYAX's Earnings Yield (Greenblatt) (%) is ranked higher than
69% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. DYAX: -0.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DYAX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -2.1  Med: 0.00 Max: 0
Current: -0.3
-2.1
0

More Statistics

Revenue(Mil) $98
EPS $ -0.21
Short Percentage of Float2.93%
52-Week Range $14.06 - 38.56
Shares Outstanding(Mil)147.18

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 98 116 115 372
EPS($) -0.26 -0.20 -0.23 1.05
EPS without NRI($) -0.26 -0.20 -0.23 1.05

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DY8.Germany,
Dyax Corp was incorporated in the state of Delaware in the year 1989, and merged with Protein Engineering Corporation in 1995. It is a biopharmaceutical company focused on Hereditary Angioedema and Other Plasma-Kallikrein-Mediated Disorders and Licensing and Funded Research Portfolio. The Company develops and commercializes treatments for hereditary angioedema and to identify other disorders that are mediated by plasma kallikrein. It is engaged in identifying and developing treatments for patients who experience PKM angioedema. Plasma kallikrein, an enzyme found in blood, produces bradykinin, a protein that causes blood vessels to enlarge or dilate, which can cause swelling known as angioedema. Excess plasma kallikrein activity plays a role in HAE and could potentially play a role in a number of inflammatory diseases, including Crohn's disease, psoriasis, rheumatoid arthritis, and various mast cell disorders. It also develops KALBITOR for the treatment of acute attacks of HAE. KALBITOR is currently distributed through a limited network of wholesale, hospital and specialty pharmacy arrangements. Its portfolio of product candidates being developed by licensees using its phage display technology. For KALBITOR as a treatment for HAE, its competitors include: Manufacturers of corticosteroids. Other competitors for the treatment of HAE are companies that are developing small molecule plasma kallikrein inhibitors. The preclinical study and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its products and product candidates, including KALBITOR and those of its licensees, are subject to extensive regulation by governmental authorities in the United States and other countries.
» More Articles for DYAX

Headlines

Articles On GuruFocus.com
Mario Gabelli Comments on Dyax Corp Jan 29 2016 
Chuck Royce Makes Big Gains on Divestitures Jan 03 2016 
Voltari Corp. (VLTC) Under Carl Icahn Umbrella, Dyax Corp. (DYAX) Potential Angioedema Preventive Tr Apr 01 2015 
Weekly CFO Buys Highlight: DYAX, IBI, FARM, TAP, DBM Mar 19 2011 
Dyax Corp. (DYAX) CEO Gustav Christensen buys 10,000 Shares Mar 15 2011 
Dyax Corp. (DYAX) CEO Gustav Christensen buys 10,000 Shares Mar 15 2011 
Dyax Corp. Reports Operating Results (10-K) Mar 02 2011 
Dyax Corp. Reports Operating Results (10-Q) Nov 02 2010 
Dyax Corp. (DYAX) CEO Gustav Christensen buys 5,000 Shares Sep 15 2010 
Dyax Corp. (DYAX) CFO George V Migausky buys 12,000 Shares Aug 25 2010 

More From Other Websites
Shire sets out bullish guidance for 2016 after beating quarterly forecasts Feb 11 2016
Here Are The Most Notable Insider Transactions Hitting The Market Jan 26 2016
Shire stays mum on Burlington facilities, employees in wake of Dyax acquisition Jan 25 2016
DYAX CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of... Jan 22 2016
Shire Completes Acquisition of Dyax Jan 22 2016
Shire Completes Acquisition of Dyax Jan 22 2016
Technical Scrutiny on Biotechnology Stocks -- Gilead Sciences, Sarepta Therapeutics, Dyax Corp., and... Jan 21 2016
3 Stocks Making New 52-Week Highs Jan 20 2016
[$$] The Judge Who Shoots Down Merger Lawsuits Jan 11 2016
[$$] The Judge Who Shoots Down Merger Lawsuits Jan 10 2016
The Zacks Analyst Blog Highlights: ALPS Medical Breakthroughs ETF, Anacor Pharmaceuticals, Dyax,... Dec 29 2015
5 Top Performing Stocks of the Top ETF of 2015 Dec 28 2015
Here are the 20 top-performing stocks in Mass. for 2015 Dec 14 2015
DYAX CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 11 2015
Dyax Corp. Sets January 21, 2016 As Date of Special Stockholder Meeting To Vote On Its Proposed... Dec 11 2015
Dyax Corp. Sets January 21, 2016 As Date of Special Stockholder Meeting To Vote On Its Proposed... Dec 11 2015
DYAX CORP Financials Dec 08 2015
Dyax Corp. Presents Phase 1b DX-2930 Data at the American College of Allergy, Asthma, and Immunology... Dec 08 2015
Dyax Corp. Presents DX-4012 Data at the 2015 American Society of Hematology Annual Meeting Dec 08 2015
Dyax Corp. Announces Early Termination of Hart-Scott-Rodino Waiting Period Dec 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK